⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCGN News
Ocugen, Inc. Common Stock
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
globenewswire.com
OCGN
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
globenewswire.com
OCGN
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
globenewswire.com
OCGN
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
globenewswire.com
OCGN
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
globenewswire.com
OCGN
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
globenewswire.com
OCGN
Cell and Gene Therapy Market to Exceed US$105B by 2033, Driving Strategic Value Across Healthcare Portfolios | According to DataM Intelligence
prnewswire.com
EDIT
NTLA
RPTX
NVS
GILD
BMY
VRTX
CRL
OCGN
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
globenewswire.com
OCGN
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight
globenewswire.com
JNJ
OCGN
APLS
ALXN
IONS
BLTE
LCTX
REGN
AVNX
NBIX
STE
COG
AVD
OCUGEN
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
globenewswire.com
OCGN